{"id":230581,"date":"2021-04-05T09:00:00","date_gmt":"2021-04-05T08:00:00","guid":{"rendered":"https:\/\/eu.intelligentlabs.org\/kas-ir-fosfatidilserins\/"},"modified":"2021-04-05T09:00:00","modified_gmt":"2021-04-05T08:00:00","slug":"kas-ir-fosfatidilserins","status":"publish","type":"post","link":"https:\/\/eu.intelligentlabs.org\/lv-lv\/kas-ir-fosfatidilserins\/","title":{"rendered":"Kas ir fosfatidilser\u012bns?"},"content":{"rendered":"\n

Kas ir fosfatidilser\u012bns? Paties\u012bb\u0101, m\u0113s uz\u0146emam fosfatidilser\u012bnu katru dienu, bet, diem\u017e\u0113l, vairumam no mums, t\u0101 t\u0101pat pietr\u016bkst. Fosfatidilser\u012bns ir atrodams vair\u0101kos \u0113dienos, ieskaitot soju (kas ir t\u0101s galvenais avots), balt\u0101s pupi\u0146as, olu dzeltenumu, vistu aknas un lielopu aknas. Diem\u017e\u0113l, m\u016bsu \u0137erme\u0146iem to ir gr\u016bti absorb\u0113t pietieko\u0161os daudzomos no p\u0101rtikas avotiem. \u0160aj\u0101 rakst\u0101 m\u0113s paskaidrosim, kas ir fosfatidilser\u012bns un k\u0101d\u0113\u013c tas ir pats efekt\u012bv\u0101kais dab\u012bgais nootropi\u0137is.<\/p>\n\n\n\n

Kas ir fosfatidilser\u012bns?<\/strong><\/h2>\n\n\n\n
\"Nervu<\/figure>\n\n\n\n

Fosfatidilser\u012bns ir \u0161\u016bnas membr\u0101nas fosfolip\u012bds, tas ir atrodams katr\u0101 no m\u016bsu 20 triljonu \u0161\u016bnu. Tas veido aptuveni 2-15% m\u016bsu \u0161\u016bnu membr\u0101nas, bet augst\u0101k\u0101s fosfatidilser\u012bna l\u012bme\u0146u koncentr\u0101cijas ir atrodamas smadzen\u0113s, kur tas ir \u012bpa\u0161i svar\u012bgs un veido 10-20% kop\u0113jiem fosfolip\u012bdu kr\u0101jumiem (1).<\/p>\n\n\n\n

Smadze\u0146u un nervu sist\u0113mas pamatvien\u012bbas sauc par neironiem (nervu \u0161\u016bn\u0101m). Neirona izvades da\u013ca tiek saukta par aksonu (nervu \u0161\u016bnu); kad neirons v\u0113las parun\u0101t ar citu neironu, tas s\u016bta elektrisku zi\u0146ojumu caur aksonu. Aksoni ir p\u0101rkl\u0101ti ar sl\u0101ni, ko sauc par miel\u012bna apvalku. Miel\u012bna apvalks aizsarg\u0101 un aksonu, \u013caujot elektrosign\u0101liem starp neironiem p\u0101raid\u012bties \u0101tri un efekt\u012bvi<\/p>\n\n\n\n

Miel\u012bna apvalks ir \u012bpa\u0161i bag\u0101t\u012bgs ar fosfatidilser\u012bnu. P\u0113d\u0113j\u0101 laik\u0101 ir atkl\u0101ts, ka fosfatidilser\u012bns uzlabo nervu darb\u012bbu un pal\u012bdz atjaunot boj\u0101tu neironu funkciju (2).<\/p>\n\n\n\n

\"fosfatidizer\u012bna<\/figure>\n\n\n\n

Fosfatidilser\u012bns Smadzen\u0113s<\/strong><\/h3>\n\n\n\n

Nesen atkl\u0101t\u0101 par fosfatidilser\u012bna loma svar\u012bgas sign\u0101la p\u0101rraides aktiviz\u0113\u0161an\u0101 un galveno neirotransmiteru izdal\u012b\u0161an\u0101s (acetilhol\u012bna, norepinefr\u012bna, seroton\u012bna un dopam\u012bna) un receptoru funkcijas modul\u0113\u0161an\u0101 ir atjaunojusi interesi par fosfatidilser\u012bna noz\u012bmi smadze\u0146u darb\u012bb\u0101 (3-5).<\/p>\n\n\n\n

L\u016bk ir att\u0113ls, kas ar \u0161\u016bnu membr\u0101nu fosfolip\u012bdu divsl\u0101ni:<\/p>\n\n\n\n

Acetilhol\u012bnu (Ach) bie\u017ei d\u0113v\u0113 par \u201cviedo\u201d neirotransmiteru, jo tas ir vit\u0101li nepiecie\u0161ams m\u0101c\u012bb\u0101m, atmi\u0146ai un uzman\u012bbas palielin\u0101\u0161anai<\/p>\n\n\n\n

caur \u2018hol\u012bner\u0123isk\u0101m\u2019 transmisij\u0101m (acetilhol\u012bna sinaps\u0113m). Tas sast\u0101v no no acetil-CoA un hol\u012bna, t\u0101p\u0113c hol\u012bns bie\u017ei tiek pieskait\u012bts Nootrop\u012bniem. Norepinefr\u012bns (aka Noradrenal\u012bns) tiek saist\u012bts ar gar\u012bgo ener\u0123iju, koncentr\u0113\u0161anos un modr\u012bbu. Dopam\u012bns ir saist\u012bts ar motiv\u0101ciju un koncentr\u0113\u0161anos. Seroton\u012bns tiek saist\u012bts ar labu garast\u0101vokli un uzlabotu miegu, seroton\u012bna tr\u016bkums ir cie\u0161i saist\u012bts ar depresiju un sliktu koncentr\u0113\u0161anos.<\/p>\n\n\n\n

Tie\u0161i \u0161ie neirotransmiteru efekti liek cilv\u0113kiem, kuri lieto fosfatidilser\u012bnu, iev\u0113rot skaidri j\u016btamu at\u0161\u0137ir\u012bbu smadze\u0146u darb\u012bbas asum\u0101 un skaidrum\u0101. Tiem ir viegl\u0101k koncentr\u0113ties, koncentr\u0113ties, atcer\u0113ties v\u0101rdus un vietas no pag\u0101tnes, veidot skaidr\u0101kus un rait\u0101kus teikumus, k\u0101 ar\u012b saglab\u0101t labu garast\u0101vokli un uzlabotu miegu.<\/p>\n\n\n\n

Fosfatidilser\u012bna priek\u0161roc\u012bbas<\/strong><\/h2>\n\n\n\n

Nesen veiktos p\u0113t\u012bjums ir atkl\u0101ts, ka fosfatidilser\u012bns atvieglo atmi\u0146as trauc\u0113jumus<\/a>, k\u0101di rodas norm\u0101la noveco\u0161anas procesa laik\u0101 (6).<\/p>\n\n\n\n

\"Hol\u012bner\u0123isk\u0101s<\/figure>\n\n\n\n

V\u0113l viena svar\u012bga fosfatidilser\u012bna priek\u0161roc\u012bba ir t\u0101 ietekme uz hipotal\u0101mu un hipokampu smadzen\u0113s. Abas \u0161\u012bs zonas darbojas kop\u0101, regul\u0113jot kortizola izdal\u012b\u0161anos, kas ir galvenais \u0137erme\u0146a stresa hormons, kas izdal\u0101s no virsnieru garozas. Kortizols darbojas p\u0113c atgriezenisk\u0101s saites, lai, atbr\u012bvojoties pietiekami daudz, hipotal\u0101ms un hipokamps to nojaustu un samazin\u0101tu no hipotal\u0101ma atbr\u012bvot\u0101 CRH (kortikotrop\u012bnu atbr\u012bvojo\u0161\u0101 hormona) daudzumu, k\u0101 rezult\u0101t\u0101 hipof\u012bze rada maz\u0101k AKTH (adrenokortikotropo hormonu), kas liek virsnier\u0113m ra\u017eot maz\u0101k kortizola.<\/p>\n\n\n\n

Tom\u0113r, ja kortizola l\u012bmenis paaugstin\u0101s hroniski, piem\u0113ram, ja mums hroniska stresa rezult\u0101t\u0101, hipotal\u0101ms un hipokamps zaud\u0113 jut\u012bbu pret to, t\u0101d\u0113\u013c CRH un ACTH izdal\u012b\u0161an\u0101s netiek noraid\u012bta, un kortizola ra\u017eo\u0161ana virsnier\u0113s netiek p\u0101rtraukta. Tas noz\u012bm\u0113, ka galu gal\u0101 kortizola l\u012bmenis k\u013c\u016bst hroniski augsts. Fosfatidilser\u012bns var atk\u0101rtoti sensibiliz\u0113t hipotal\u0101ma un hipokampa \u0161\u016bnas pret kortizolu, lai t\u0101s atkal \u2018dzird\u0113tu\u2019 atgriezenisk\u0101so saiti un samazin\u0101tu CRH un AKTH, kas samazina kortizola ra\u017eo\u0161anu (5,6,7).<\/p>\n\n\n\n

Fosfatidilser\u012bna l\u012bmenis organism\u0101 samazin\u0101s, novecojot, un samazin\u0101ts fosfatidilser\u012bna daudzums tiek saist\u012bts ar kognit\u012bviem trauc\u0113jumiem, ieskaitot Alcheimera slim\u012bbas pato\u0123en\u0113zi. (AS) (10, 11).<\/p>\n\n\n\n

\"lietojiet<\/figure>\n\n\n\n

P\u0113t\u012bjumi Pier\u0101da Fosfatidilser\u012bna Iedarb\u012bbu k\u0101 Nootropiskajam L\u012bdzeklim<\/strong><\/h2>\n\n\n\n

Nesen\u0101, 2020. Gad\u0101 veikt\u0101 p\u0113t\u012bjum\u0101, tika atkl\u0101ts, ka uztura bag\u0101tin\u0101\u0161ana<\/a> ar fosfatidilser\u012bnu iev\u0113rojami palielin\u0101ja notur\u012bbu pret oksidat\u012bvo stresu, mazin\u0101ja noveco\u0161an\u0101s reakciju un, papildus dz\u012bves ilguma pagarin\u0101\u0161anai, var rad\u012bt profilaktisku ietekmi uz vecumu saist\u012bt\u0101m slim\u012bb\u0101m (12).<\/p>\n\n\n\n

Oksidat\u012bvajam stresam ir galven\u0101 loma ar vecumu saist\u012btu slim\u012bbu, tostarp artr\u012bta, diab\u0113ta, demences, v\u0113\u017ea, aterosklerozes, asinsvadu slim\u012bbu, aptauko\u0161an\u0101s, osteoporozes un metabolisko sindromu att\u012bst\u012bb\u0101, k\u0101 to liecina vair\u0101ki p\u0113t\u012bjumi (13,14).<\/p>\n\n\n\n

Cit\u0101 nesen veikt\u0101 p\u0113t\u012bjum\u0101, kur\u0101 nov\u0113roja fosfatidilser\u012bna lomu, atkl\u0101ja, ka uztura bag\u0101tin\u0101\u0161ana ar (300-800 mg dien\u0101) dro\u0161i pal\u0113nina vai apv\u0113r\u0161 nervu \u0161\u016bnu izmai\u0146as un pasliktin\u0101\u0161anos, vienlaic\u012bgi atbalstot kognit\u012bv\u0101s funkcijas. Tas ietver \u012bstermi\u0146a atmi\u0146as veido\u0161anos, ilgtermi\u0146a atmi\u0146as konsolid\u0101ciju, sp\u0113ju rad\u012bt jaunas atmi\u0146as, sp\u0113ju atg\u016bt atmi\u0146as, sp\u0113ju iem\u0101c\u012bties un atsaukt inform\u0101ciju, sp\u0113ju koncentr\u0113t uzman\u012bbu un koncentr\u0113ties, sp\u0113ju pamatot un risin\u0101t probl\u0113mas, valodas prasmes un sp\u0113ju komunic\u0113t. Uzlabojas ar\u012b kust\u012bbu funkcijas, \u012bpa\u0161i \u0101tras reakcijas un refleksus (15).<\/p>\n\n\n\n

2011. gad\u0101 veikt\u0101 p\u0113t\u012bjum\u0101, p\u0101rbaud\u012bja 18 koled\u017eas vecuma v\u012brie\u0161us p\u0113c 14 dienu uztura bag\u0101tin\u0101\u0161anas ar 400 mg fosfatidilser\u012bna s\u0113rijveida at\u0146em\u0161anas test\u0101 (t.i., skaitot atpaka\u013c no 100 l\u012bdz 7, 6 vai 3 utt.). Vi\u0146i atkl\u0101ja, ka grupa, kas tika papildin\u0101ta ar fosfatidilser\u012bnu, sal\u012bdzin\u0101jum\u0101 ar placebo grupu, par 20% samazin\u0101ja pareizam apr\u0113\u0137inam nepiecie\u0161amo laiku, par 39% samazin\u0101ja kop\u0113jo k\u013c\u016bdu daudzumu un par 13% palielin\u0101ja pareizo apr\u0113\u0137inu skaitu (16).<\/p>\n\n\n\n

\"Hol\u012bner\u0123isk\u0101s<\/figure>\n\n\n\n

Divos atkl\u0101tos p\u0113t\u012bjumos ar vec\u0101kiem dal\u012bbniekiem, kuri cie\u0161 no vieglas kognit\u012bv\u0101s pasliktin\u0101\u0161an\u0101s (atmi\u0146as zudums, ko izraisa noveco\u0161ana cilv\u0113kiem, kuri cit\u0101di ir kl\u012bniski veseli), tika konstat\u0113ts, ka papildin\u0101\u0161ana ar 300 mg fosfatidilser\u012bna dien\u0101 uzlaboja kognit\u012bvo veiktsp\u0113ju verb\u0101l\u0101s m\u0101c\u012b\u0161an\u0101s, verb\u0101l\u0101s p\u0101rbaudes testos, atsauk\u0161ana, verb\u0101l\u0101 pl\u016bdums, vizu\u0101l\u0101 m\u0101c\u012b\u0161an\u0101s, uzman\u012bba, komunik\u0101cijas prasmes, iniciat\u012bva, socializ\u0101cija un pa\u0161pietiekam\u012bba (17,18). L\u012bdz\u012bgs p\u0113t\u012bjums, kas ilga 90 dienas, non\u0101ca pie t\u0101diem pa\u0161iem rezult\u0101tiem, bet ar\u012b papildus atkl\u0101ja, ka p\u0113t\u012bjuma dal\u012bbnieki uzlaboja sp\u0113ju atcer\u0113ties v\u0101rdus un sejas (19)<\/p>\n\n\n\n

Citos atmi\u0146as un fosfatidilser\u012bna p\u0113t\u012bjumos atkl\u0101ja, ka vec\u0101ka gadag\u0101juma cilv\u0113ku, kuri juta atmi\u0146as pasliktin\u0101\u0161anos, sp\u0113ja atcer\u0113ties v\u0101rdus palielin\u0101j\u0101s par 42% (20), papildus tam ar\u012b iev\u0113rojami uzlaboj\u0101s atmi\u0146a, izpildfunkcija un gar\u012bg\u0101 elast\u012bba (21), p\u0113c uztura bag\u0101tin\u0101\u0161anas ar 300 mg dien\u0101.<\/p>\n\n\n\n

2015. gad\u0101 tika konstat\u0113ts, ka uztura bag\u0101tin\u0101\u0161ana ar fosfatidilser\u012bnu mazina vec\u0101ka gadag\u0101juma cilv\u0113ku galvenos depresijas simptomus, samazinot kortizola b\u0101zes koncentr\u0101ciju  (22).<\/p>\n\n\n\n

2016. gad\u0101 p\u0113t\u012bjums par\u0101d\u012bja saist\u012bbu starp uztura bag\u0101tin\u0101t\u0101jiem, kortizola regul\u0113\u0161anu, miegu, Alcheimera slim\u012bbas risku un fosfatidilser\u012bna sp\u0113ju atjaunot kortizola koncentr\u0101ciju, t\u0101d\u0113j\u0101di atvieglojot miega trauc\u0113jumus un regul\u0113t miega kvalit\u0101ti, kas atvieglo smadze\u0146u kl\u012brensu un pozit\u012bvi saglab\u0101t vai palielin\u0101t smadze\u0146u funkcijas un attiec\u012bgi samazin\u0101t kognit\u012bvo trauc\u0113jumu un demences risku (23).<\/p>\n\n\n\n

Turkl\u0101t uztura bag\u0101tin\u0101\u0161ana ar fosfatidilser\u012bnu tika saist\u012bta ar maz\u0101k stresa saj\u016btu un lab\u0101ku garast\u0101vokli jauniem pieaugu\u0161ajiem, lietojot 300 mg katru dienu m\u0113nes\u012b (24).<\/p>\n\n\n\n

Atkl\u0101jumi ar\u012b liecin\u0101ja par to, ka fosfatidilser\u012bns ir efekt\u012bvs uztura bag\u0101tin\u0101t\u0101js slodzes izrais\u012btu stresa apkaro\u0161anai un fiziolo\u0123isk\u0101 st\u0101vok\u013ca uzlabo\u0161anai. Fosfatidilser\u012bna uztura bag\u0101tin\u0101t\u0101js pal\u012bdz sportistiem sasniegt v\u0113lamo hormon\u0101lo st\u0101vokli, nom\u0101cot kortizola l\u012bme\u0146a paaugstin\u0101\u0161anos (25,26).<\/p>\n\n\n\n

Fosfatidilser\u012bns var ar\u012b pal\u012bdz\u0113t pret uzman\u012bbas defic\u012bta sindroma simptomiem. Piem\u0113ram, 2014. gada p\u0113t\u012bjums Jap\u0101n\u0101 atkl\u0101ja, ka b\u0113rni vecum\u0101 no 4 l\u012bdz 14 gadiem, kuri bag\u0101tin\u0101ja uzturu ar 200 mg fosfatidilser\u012bna dien\u0101, iev\u0113rojami uzlaboja \u012bstermi\u0146a atmi\u0146u, k\u0101 ar\u012b atviegloja neuzman\u012bbas probl\u0113mas un impulsivit\u0101ti (27).<\/p>\n\n\n\n

\"Uzlabojiet<\/figure>\n\n\n\n

K\u0101da ir Pareiz\u0101 Fosfatidilser\u012bna Deva?<\/strong><\/h2>\n\n\n\n

Ieteicam\u0101 fosfatidilser\u012bna deva ir 100mg 3 reizes dien\u0101, kop\u0101 ar malt\u012bt\u0113m<\/a>. Ir pier\u0101d\u012bts, ka \u0161\u012b deva pal\u012bdz cilv\u0113kiem, kuri cie\u0161 no kognit\u012bv\u0101s pasliktin\u0101\u0161an\u0101s, un tiem, kuri v\u0113las uzlabot kognit\u012bvo funkciju (28).<\/p>\n\n\n\n

Tom\u0113r jebkura uztura bag\u0101tin\u0101t\u0101ja devu ir svar\u012bgi izv\u0113l\u0113ties, pamatojoties uz j\u016bsu person\u012bgaj\u0101m pras\u012bb\u0101m, nav t\u0101da viena standarta, kas der\u0113tu visiem. Tas jo \u012bpa\u0161i attiecas uz cilv\u0113kiem, kuri mekl\u0113 fosfatidilser\u012bnu, lai pal\u012bdz\u0113tu samazin\u0101t augstu kortizola l\u012bmeni, lai pal\u012bdz\u0113tu stresa gad\u012bjum\u0101. Zin\u0101tniskos p\u0113t\u012bjumos esam atkl\u0101ju\u0161i, ka, lai cilv\u0113kiem ar augstu kortizola l\u012bmeni sp\u0113tu to samazin\u0101t, var b\u016bt nepiecie\u0161ams vair\u0101k nek\u0101 300 mg dien\u0101, l\u012bdz pat 800 mg dien\u0101 (15).<\/p>\n\n\n\n

Neskatoties uz to, tikl\u012bdz \u0137ermenis palielina fosfatidilser\u012bna l\u012bmeni un kortizola l\u012bmenis normaliz\u0113jas, \u0161o lielo fosfatidilser\u012bna devu var samazin\u0101t. Galvenais ir sekot veselajam sapr\u0101tam un visu simptomu izmai\u0146u apzin\u0101\u0161an\u0101s. S\u0101ciet ar 100mg dien\u0101 un l\u0113n\u0101m piel\u0101gojiet devu, pievienojot 100mg dien\u0101 ik p\u0113c 4-5 dien\u0101m. Ja k\u0101d\u0101 br\u012bd\u012b p\u0113c devas palielin\u0101\u0161anas j\u016bs k\u013c\u016bstat satraukt\u0101ks, vai ja tas nel\u0101gi ietekm\u0113 j\u016bsu miegu, t\u0101 ir paz\u012bme, ka esat p\u0101rsniedzis sev piem\u0113roto devas l\u012bmeni, un jums vajadz\u0113tu samazin\u0101t devu.<\/p>\n\n\n\n

Atsauces:<\/p>\n\n\n\n

(1) Zanotti, A., Rubini, R., Calderini, G., and Toffano, G., 1987, Pharmacological properties of phosphatidylserine: effects on memory function, in: \u201cNutrients and Brain Function,\u201d W.B. Essman, ed., Karger, Basel, pp. 95\u2013102.<\/p>\n\n\n\n

(2) Abay ZC, Wong MY, Teoh JS, Vijayaraghavan T, Hilliard MA,Neumann B (2017) Phosphatidylserine save-me signals drive functional recovery of severed axons in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 114, E10196\u2013E10205. 13.<\/p>\n\n\n\n

(3) Kim, H. Y., Huang, B. X., & Spector, A. A. (2014). Phosphatidylserine in the brain: metabolism and function. Progress in lipid research, 56, 1\u201318.<\/p>\n\n\n\n

(4) Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991;41:644\u20139.<\/p>\n\n\n\n

(5) Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer\u2019s disease. Psychopharmacol Bull 1992;28:61\u20136.<\/p>\n\n\n\n

(6) Lee B, Sur BJ, Han JJ, Shim I, Her S, Lee YS, Lee HJ, Hahm DH(2015) Oral administration of squid lecithin-transphos-phatidylatedphosphatidylserineimprovesmemoryimpairment in aged rats. Prog Neuropsychopharmacol BiolPsychiatry 56:1\u201310.<\/p>\n\n\n\n

(7) Monteleone P, Maj M, Beinat L, Natale M, Kemali D, Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol. 1992;42(4):385-8.<\/p>\n\n\n\n

(8) Monteleone P, Beinat L, Tanzillo C, Maj M, Kemali D, Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans, Neuroendocrinology. 1990 Sep;52(3):243-8.<\/p>\n\n\n\n

(9) Hellhammer J, Hero T, Franz N, Contreras C, Schubert M. Omega-3 fatty acids administered in phosphatidylserine improved certain aspects of high chronic stress in men. Nutr Res. 2012 Apr;32(4):241-50.<\/p>\n\n\n\n

(10) Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J,Fortier M, Bennett DA, Morris MC (2012) Plasma and brain fatty acid profiles in mild cognitive impairment andAlzheimer\u2019s disease. J Alzheimers Dis 29:691\u2013697.<\/p>\n\n\n\n

(11) Suleimanova RR, Hudz EA, Melnychuk DO, Kalachniuk LH(2017) Age-related changes phospholipids of sterlet in liver and dorsal muscles. Ukr Biochem J 89:71\u201375.<\/p>\n\n\n\n

(12) Kim, B., Park, S. Phosphatidylserine modulates response to oxidative stress through hormesis and increases lifespan via DAF-16 in Caenorhabditis elegans. Biogerontology (2020).<\/p>\n\n\n\n

(13) Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D., & Abete, P. (2018). Oxidative stress, aging, and diseases. Clinical interventions in aging, 13, 757\u2013772.<\/p>\n\n\n\n

(14) H Van Remmen, Oxidative Stress And Age-related Diseases, Innovation In Aging, Volume 2, Issue Suppl_1, 1 November 2018, Page 347.<\/p>\n\n\n\n

(15) Michael J. Glade Ph.D., Kyl Smith D.C., Phosphatidylserine and the human brain, Nutrition 31 (2015) 781\u2013786<\/p>\n\n\n\n

(16) Parker AG1, Gordon J, Thornton A, Byars A, Lubker J, Bartlett M, Byrd M, Oliver J, Simbo S, Rasmussen C, Greenwood M, Kreider RB, The effects of IQ PLUS Focus on cognitive function, mood and endocrine response before and following acute exercise, J Int Soc Sports Nutr. 2011 Oct 21;8:16.<\/p>\n\n\n\n

(17) Kidd, Parris. (1996). Phosphatidylserine; Membrane Nutrient for Memory. A Clinical and Mechanistic Assessment. Altern. Med. Rev..1<\/p>\n\n\n\n

(18) Caffara P, Santamaria V. The effects of phosphatidylserine in patients with mild cognitive decline. An open trial. Clin Trials J 1987;24:109\u201314.<\/p>\n\n\n\n

(19) ] Schreiber S, Kampf-Sherf O, Gorfine M, Kelly D, Oppenheim Y, Lerer B. An open trial of plant-source derived phosphatidylserine for treatment of age-related cognitive decline. Isr J Psychiatry Relat Sci 2000;37:302\u20137.<\/p>\n\n\n\n

(20) Richter Y, Herzog Y, Cohen T, Steinhart Y. The effect of phosphatidylserine containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: a pilot study. Clin Interv Aging 2010;5: 313\u20136.<\/p>\n\n\n\n

(21) Richter Y, Herzog Y, Lifshitz Y, Hayun R, Zchut S. The effect of soybean derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study. Clin Interv Aging 2013;8: 557\u201363.<\/p>\n\n\n\n

(22) Komori T. The Effects of Phosphatidylserine and Omega-3 Fatty Acid-Containing Supplement on Late Life Depression. Ment Illn 2015;7:5647.<\/p>\n\n\n\n

(23) Pistollato, F., Sumalla Cano, S., Elio, I., Masias Vergara, M., Giampieri, F., & Battino, M. (2016). Associations between Sleep, Cortisol Regulation, and Diet: Possible Implications for the Risk of Alzheimer Disease. Advances in nutrition (Bethesda, Md.), 7(4), 679\u2013689.<\/p>\n\n\n\n

(24) Benton D, Donohoe RT, Sillance B, Nabb S: The Influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. Nutr Neurosci. 2001, 4 (3): 169-178.<\/p>\n\n\n\n

(25) Starks, M.A., Starks, S.L., Kingsley, M. et al. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr 5, 11 (2008).<\/p>\n\n\n\n

(26) Hellhammer, J., Vogt, D., Franz, N., Freitas, U., & Rutenberg, D. (2014). A soy-based phosphatidylserine\/ phosphatidic acid complex (PAS) normalizes the stress reactivity of hypothalamus-pituitary-adrenal-axis in chronically stressed male subjects: a randomized, placebo-controlled study. Lipids in health and disease, 13, 121.<\/p>\n\n\n\n

(27) Hirayama S, Terasawa K, Rabeler R, Hirayama T, Inoue T, Tatsumi Y, Purpura M, J\u00e4ger R, The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial, J Hum Nutr Diet. 2014 Apr;27 Suppl 2:284-91.<\/p>\n\n\n\n

(28) \u201cPhosphatidylserine,\u201d Examine.com<\/a>, published on 10 April 2013, last updated on 14 June 2018.<\/p>\n","protected":false},"excerpt":{"rendered":"

Kas ir fosfatidilser\u012bns? Paties\u012bb\u0101, m\u0113s uz\u0146emam fosfatidilser\u012bnu katru dienu, bet, diem\u017e\u0113l, vairumam no mums, t\u0101 t\u0101pat pietr\u016bkst. Fosfatidilser\u012bns ir atrodams vair\u0101kos \u0113dienos, ieskaitot soju (kas ir t\u0101s galvenais avots), balt\u0101s pupi\u0146as, olu dzeltenumu, vistu aknas un lielopu aknas. Diem\u017e\u0113l, m\u016bsu \u0137erme\u0146iem to ir gr\u016bti absorb\u0113t pietieko\u0161os daudzomos no p\u0101rtikas avotiem. \u0160aj\u0101 rakst\u0101 m\u0113s paskaidrosim, kas…<\/p>\n","protected":false},"author":2,"featured_media":132171,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[2958],"tags":[2977],"coauthors":[],"class_list":["post-230581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uzturs","tag-fosfatidilserins"],"taxonomy_info":{"category":[{"value":2958,"label":"Uzturs"}],"post_tag":[{"value":2977,"label":"fosfatidilser\u012bns"}]},"featured_image_src_large":["https:\/\/eu.intelligentlabs.org\/wp-content\/uploads\/2018\/02\/phosphatidylserine-the-most-effective-natural-nootropic-02-1024x512.jpg",1024,512,true],"author_info":{"display_name":"David Pashley","author_link":"https:\/\/eu.intelligentlabs.org\/lv-lv\/author\/david\/"},"comment_info":0,"category_info":[{"term_id":2958,"name":"Uzturs","slug":"uzturs","term_group":0,"term_taxonomy_id":2958,"taxonomy":"category","description":"","parent":0,"count":42,"filter":"raw","cat_ID":2958,"category_count":42,"category_description":"","cat_name":"Uzturs","category_nicename":"uzturs","category_parent":0}],"tag_info":[{"term_id":2977,"name":"fosfatidilser\u012bns","slug":"fosfatidilserins","term_group":0,"term_taxonomy_id":2977,"taxonomy":"post_tag","description":"","parent":0,"count":2,"filter":"raw"}],"wpml":{"language":"lv-lv","is_original":true,"original_post_id":230581,"translations":{"lv-lv":{"id":230581,"language":"lv-lv","is_original":true}}},"_links":{"self":[{"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/posts\/230581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/comments?post=230581"}],"version-history":[{"count":0,"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/posts\/230581\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/media\/132171"}],"wp:attachment":[{"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/media?parent=230581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/categories?post=230581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/tags?post=230581"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/eu.intelligentlabs.org\/lv-lv\/wp-json\/wp\/v2\/coauthors?post=230581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}